Molecule Holdings Receivables

The latest receivables for ERV2.F is $350K as of July 2023. That compares with $710K in the prior-year period — down 50.5% year over year. Investors often review this figure alongside Molecule Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, ERV2.F's receivables moved from $710K to $350K — a 50.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Molecule Holdings's operating scale or balance-sheet position.

A receivables figure of $350K for ERV2.F is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ERV2.F's receivables ($350K), review year-over-year change from $710K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.